Caris & Co Upgrades Illumina (ILMN) to Above Average
More News related to ILMN
- Illumina (ILMN) Approves New $100M Buyback
- Illumina Announces $100 Million Share Repurchase Program
- Illumina to Present at the Piper Jaffray "Unplugged" Health Care Conference
- Leerink Swann Maintains an 'Outperform' on Illumina (ILMN); Near-Term Negative, Long-Term Catalyst Rich
- Auriga Reiterates a 'Buy' on Illumina (ILMN); Lowers PT & Estimates
More News related to Upgrades
- Enbridge (ENB) Raises Qtr. Dividend by 15% to $0.425; Gives FY10 EPS Outlook
- Watson Pharmaceuticals (WPI) Completes Acquisition of Arrow Group; Deal Accretive to 2010 Earnings
- The Pantry (PTRY) Reports Q4 EPS of $0.60; Guides FY10 Merchandise Sales
- G-III Apparel Group (GIII) Posts Q3 EPS of $1.87, Beats Estimates; Raises Guidance
- Regency Centers (REG) Affirms Fy09 Guidance and Provides Fy10 FFO Guidance
Caris & Co upgrades Illumina (Nasdaq: ILMN) from Average to Above Average. Price target increased to $42.
To see more analyst ratings on ILMN Click Here.
Illumina, Inc. engages in the development, manufacture, and marketing of integrated systems for the analysis of genetic variation and biological function.
Related Categories
UpgradesStocks Mentioned
-0.59Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
